oa Lack of reversibility for NOACs

References

1. Kaba RA, Ahmed O, Cannie D. ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation. Glob Cardiol Sci Pract. 2013; 2013:4:354–356.
   [Google Scholar]
2. Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012 Dec; 46:12:1627–1636.
   [Google Scholar]
3. Sarma A. Novel Oral Anticoagulants and Lack of Reversibility. Cardiosource.org. Accessed 1/11/2014.
4. Laulicht B, Bakhru S, Lee C, Baker C, Jiang X, Mathiowitz E, Costin J, Steiner S. Small Molecule Antidote for Anticoagulants. Circulation. 2012 Nov; 126:21S:A11395.
   [Google Scholar]
5. Mark C, Vandana M, Michael K, Genmin L, Conley PB, Stanley H, Castillo J, Hutchaleelaha A, Karbarz M, Lin JP, Barron L, Russell S, Levy GG, Connolly S, Curnutte JT. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors. Blood. 2013 Oct; 122:21:3636.
   [Google Scholar]